Search This Blog

Friday, September 28, 2018

Immutep initiated at B. Riley FBR


Immutep initiated with a Buy at B. Riley FBR. B. Riley FBR analyst Dylan Dupuis started Immutep with a Buy rating and $7.75 price target. The analyst views the company as a leader in LAG-3 immunotheraphy.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)